Clinical trial
Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy…
NCT00388999 · Enzon Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00388999 |
|---|---|
| Title | Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant |
| Official title | Multi-Center,Open-Label,Randomized,Phase 1B Study Evaluating Safety & Tolerability of Intravenous rhMBL in Pts With Multiple Myeloma Receiving Melphalan-Based High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant |
| Lead sponsor | Enzon Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL) |
| Enrollment | 46 |
| Start date | Sep 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Oct 17, 2006 |
| Last update posted | Dec 5, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: